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Introduction
Radiation is an integral part of melanoma therapy, particu-
larly for patients with symptomatic metastases. Efficient
killing of tumor cells by radiation has been shown in
immunocompromised mouse models to be enhanced
greatly with transfer of a functioning immune system, par-
ticularly CD8+ T cells. In a subset of patients, addition of
radiation to immunotherapy has also enhanced immune
system-mediated tumor cell kill in non-irradiated areas,
termed abscopal effect. This effect is thought to be a result
of increased shedding of tumor antigens upon radiother-
apy that primes the immune system to establish a more
robust attack on melanoma cells throughout the body.
Whether or not brain metastases in the blood brain barrier
can be used to develop an abscopal effect is unknown. Pre-
clinical reports support synergism between PD-1 inhibi-
tion and radiation in tumor killing and prolonged survival.
Methods
To assess the extent of abscopal effect in mice models
simulating brain metastasis, we measured the degree to
which radiation enhances anti-PD1 immunotherapy of
non-irradiated tumor control. 2.0×103 luciferase-expres-
sing B16 melanoma cells were transplanted intracranially
and 8.0×105 cells were transplanted subcutaneously into
C57BL/6 mice to establish brain and flank tumors.
Anti-PD1 and IgG treatment groups received 6 Gy irradia-
tion to the brain or flank tumor respectively. Preliminary
data suggest this dose is tolerated without obvious side
effects and capable of partly reducing tumor growth. Lead
shielding was used to limit radiation to vital organs and
the contralateral tumor. Tumor growth was measured by
IVIS bioluminescence imaging.
Results
Anti-PD1 therapy significantly affected brain tumor
growth and survival. Mean brain tumor growth was signif-
icantly lower for anti-PD1 treated groups and mean survi-
val was longer for anti-PD1 treated mice than for IgG
treated mice (26.4 vs. 19.8 days, p < 0.001). Relative to
mice receiving no irradiation and those receiving both IgG
treatment and head tumor irradiation, flank tumor growth
rate was lower for mice receiving anti-PD1 treatment and
head tumor irradiation, suggesting a possible abscopal
effect. Mean flank tumor growth was lowest in mice
receiving a combination of anti-PD1 treatment and flank
tumor irradiation. Anti-PD1 treatment was also associated
with enhanced numbers of CD8+ T cells in the tumor
microenvironment.
Conclusion
This is the first study to show that melanoma brain
metastases, commonly radiated for palliation, have the
potential to enhance systemic immunotherapy effects on
non-irradiated melanoma tumors. Ongoing studies will
examine additional melanoma cell lines as well as immu-
nological changes in the microenvironment and T cell
function.
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